Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering's Specialty Focus Includes Alzheimer's, Oncology

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schering-Plough's specialty drug pipeline - part of big pharma's overall efforts to hedge against the dwindling primary care market - includes several potential first-in-class or best-in-class compounds addressing oncology, Alzheimer's disease, Parkinson's disease and other specialty areas

You may also be interested in...



Schering-Plough To Hone Its Edge In “Build The Base” Phase

Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

BMS Outlines Clinical Trial Disruptions, Reassures Supply Chain Secure

The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.

Topics

UsernamePublicRestriction

Register

PS004014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel